Back to top
more

Apellis Pharmaceuticals (APLS)

(Real Time Quote from BATS)

$37.70 USD

37.70
17,789

+0.31 (0.83%)

Updated Jul 25, 2024 09:51 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth A Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (83 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Vertex (VRTX) Q3 Earnings Beat, Sales Miss, Raises '23 View

by Zacks Equity Research

Vertex's (VRTX) third-quarter results reflect a year-over-year increase in revenues. The company raises its net product sales guidance for 2023.

Editas (EDIT) Q3 Earnings & Revenues Beat, Pipeline in Focus

by Zacks Equity Research

Editas' (EDIT) third-quarter 2023 results reflect a year-over-year increase in revenues. The stock of the company rises 18%.

Ultragenyx (RARE) Q3 Earnings and Revenues Miss Estimates

by Zacks Equity Research

Ultragenyx (RARE) reports weaker-than-expected third-quarter 2023 results, missing earnings and sales estimates. Management reiterates the 2023 financial outlook.

Acadia (ACAD) Q3 Earnings and Sales Beat Estimates, Stock Up

by Zacks Equity Research

Acadia (ACAD) reports better-than-expected third-quarter 2023 results as both earnings and sales beat estimates. The stock rises in after-market hours.

Pacira (PCRX) Q3 Earnings and Revenues Miss, '23 View Updated

by Zacks Equity Research

Pacira (PCRX) announces weaker-than-expected third-quarter 2023 results. The company streamlines its 2023 guidance for net Exparel sales.

Apellis (APLS) Q3 Loss Wider Than Expected, Syfovre Drives Sales

by Zacks Equity Research

Apellis' (APLS) third-quarter 2023 bottom line misses estimates, while the top line beats the same. Newly approved product, Syfovre, drives sales in the reported quarter.

Novo Nordisk (NVO) Q3 Earnings and Sales Beat, 2023 View Up

by Zacks Equity Research

Novo Nordisk (NVO) reports encouraging third-quarter results, beating both earnings and sales estimates, driven by strong sales of diabetes and obesity care products. Management raises 2023 guidance.

Apellis Pharmaceuticals, Inc. (APLS) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Apellis Pharmaceuticals, Inc. (APLS) delivered earnings and revenue surprises of -39.29% and 9.81%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

Can High Benefits and Expenses Affect Cigna (CI) Q3 Earnings?

by Zacks Equity Research

Cigna's (CI) third-quarter results are likely to reflect growth in medical customers and pharmacy revenues.

Is a Surprise Coming for Apellis (APLS) This Earnings Season?

by Zacks Equity Research

Apellis (APLS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Will Lower CenterWell Profit Hurt Humana's (HUM) Q3 Earnings?

by Zacks Equity Research

Humana's (HUM) third-quarter results are likely to reflect higher investment income and premiums.

Will Bionano Genomics, Inc. (BNGO) Report Negative Q3 Earnings? What You Should Know

by Zacks Equity Research

Bionano Genomics, Inc. (BNGO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Wall Street Analysts Predict a 51.91% Upside in Apellis Pharmaceuticals, Inc. (APLS): Here's What You Should Know

by Zacks Equity Research

The consensus price target hints at a 51.9% upside potential for Apellis Pharmaceuticals, Inc. (APLS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Bioventus (BVS) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

On Bioventus' (BVS) third-quarter 2023 earnings call, investors' focus is likely to be on the sales numbers of its three business units - pain treatments, restorative therapies and surgical solutions.

The Zacks Analyst Blog Highlights Apellis, Groupon and Central Garden

by Zacks Equity Research

Apellis, Groupon and Central Garden are included in this Analyst Blog.

Best Momentum Stocks to Buy for October 24th

by Zacks Equity Research

APLS, GRPN and CENTA made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on October 24, 2023.

Dynavax (DVAX) to Report Q3 Earnings: Will It Beat Estimates?

by Zacks Equity Research

On Dynavax's (DVAX) third-quarter earnings call, investors' focus is likely to be on the sales performance of the company's hepatitis B vaccine, HEPLISAV-B.

What's in the Cards for Encompass Health (EHC) in Q3 Earnings?

by Zacks Equity Research

Encompass Health's (EHC) Q3 results are likely to reflect improved inpatient volumes and bed additions, offset by higher operating expenses.

New Strong Buy Stocks for October 24th

by Zacks Equity Research

MFA, GFF, OPI, APLS and GRPN have been added to the Zacks Rank #1 (Strong Buy) List on October 24, 2023.

What's in the Cards for Universal Health (UHS) in Q3 Earnings?

by Zacks Equity Research

Universal Health's (UHS) Q3 results are likely to benefit from higher patient volumes at its acute care hospitals and behavioral health facilities, partly offset by increased physician expenses.

Merck (MRK) Inks Deal With Daiichi to Develop Cancer Drugs

by Zacks Equity Research

Per the terms, Merck (MRK) and Daiichi Sankyo will develop and market three ADC drugs to treat multiple types of cancer. Following the execution, Merck will make an upfront payment of $4 billion.

Will Rising Costs Hurt HCA Healthcare's (HCA) Q3 Earnings?

by Zacks Equity Research

HCA Healthcare's (HCA) third-quarter results are likely to reflect an increased occupancy rate and a lower average length of stay.

Can Growing Visits Aid Teladoc's (TDOC) Earnings in Q3?

by Zacks Equity Research

Teladoc's (TDOC) third-quarter results are likely to reflect growth in BetterHelp paying users.

Can Centene's (CNC) Q3 Earnings Beat on Membership Growth?

by Zacks Equity Research

Centene's (CNC) third-quarter results are likely to reflect higher premiums and lower cost of services.

UnitedHealth Group (UNH) Q3 Earnings Beat, Boosts '23 EPS View

by Zacks Equity Research

UnitedHealth Group's (UNH) management presently forecasts adjusted net EPS between $24.85 and $25.00 for 2023.